Skip to main content

Table 2 Sources of heterogeneity in all studies

From: Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review

Potential source of heterogeneity Studies (n) I2 P value
Total 8 54% 0.03
Treatment of Control    
Placebo (or small dose steroid) 4 75% 0.009
Other immunosuppressants 4 13% 0.33